罗氟司特价格一览

Roflumilast is a highly selective PDE4 (phosphodiesterase 4) inhibitor that has been approved for the treatment of chronic obstructive pulmonary disease (COPD), including the treatment of bronchitis-related cough and mucus excess in patients with severe COPD. This article will introduce in detail the prices of the original and generic drugs of roflumilast, domestic listing status, and medical insurance reimbursement status.

Prices of the original and generic drugs of Roflumilast

Currently, Roflumilast mainly exists in the form of original drugs globally, and no generic drugs have yet been launched. The following is the reference price of the original drug Roflumilast produced by AstraZeneca in the UK in different regions.

Price of the German version of AstraZeneca in the UK

Roflumilast produced by AstraZeneca in the UK, the export specification for the German version is 500μg*30 tablets, and the reference price is about US$233 per box. The specification is 500μg*90 tablets, and the reference price is about US$391 per box. These prices may vary by pharmacy and purchase channel.

The price of the Hong Kong version of AstraZeneca in the UK

The Hong Kong version of Roflumilast produced by AstraZeneca in the UK is exported to 500μg*30 tablets, and the reference price is about US$134 per box. Prices in Hong Kong are relatively low and may be more suitable for patients with limited budgets.

Knowing the price of roflumilast can help patients make more informed decisions when choosing a treatment option. Price differences in different regions also provide patients with more choices.

The domestic listing status of roflumilast

The domestic listing status of roflumilast varies by region. The following is the listing status of roflumilast in mainland China and Hong Kong.

Not marketed in mainland China

Currently, roflumilast has not been approved for marketing in mainland China. This means that patients in mainland China cannot purchase this drug through formal channels. Patients may need to consider other treatment options or obtain medications through international channels.

Listed in Hong Kong, China

Roflumilast has been approved for listing in Hong Kong, China. Patients in Hong Kong can purchase this drug at local hospital pharmacies or legal pharmacies with a doctor's prescription. The listing in Hong Kong provides patients in surrounding areas with more treatment options.

The launch of roflumilast in different regions reflects its global acceptance. For areas where it has not yet been launched, patients can follow relevant developments or obtain the drug through legal channels.

The medical insurance reimbursement status of roflumilast

The medical insurance reimbursement status of roflumilast varies from country to country and region. The following is the medical insurance reimbursement status of roflumilast in some regions.

Reimbursement by medical insurance in Europe

In many European countries, roflumilast has been included in the scope of medical insurance reimbursement. Patients can reimburse part or all of the drug costs through medical insurance, thereby reducing their financial burden. Specific reimbursement rates and conditions vary from country to country.

Reimbursement by medical insurance in Hong Kong

In Hong Kong, part of the cost of roflumilast may be reimbursed by medical insurance. Patients need to provide relevant medical certificates and prescriptions to apply for medical insurance reimbursement. For specific reimbursement ratios and procedures, please consult your local medical insurance agency.

Reimbursement by medical insurance in mainland China

Since roflumilast is not yet available on the market in mainland China, it cannot currently be reimbursed by medical insurance. If patients need to use this drug, they may need to purchase it out of pocket or obtain it through other means.

Understanding the medical insurance reimbursement status of roflumilast can help patients better plan treatment costs. For areas covered by medical insurance, patients can reduce their financial burden through medical insurance. For areas not covered, patients can pay attention to updates on relevant policies.